Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
PENDOR
1 other identifier
observational
16
1 country
1
Brief Summary
This study comprises 3 stages:
- 1.Collection of tumor and blood samples.
- 2.Creation of organoid models based on tumor samples.
- 3.Development of functional tests to predict clinical response to treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Nov 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 6, 2024
CompletedFirst Posted
Study publicly available on registry
September 19, 2024
CompletedStudy Start
First participant enrolled
November 21, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 15, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 15, 2027
November 26, 2024
November 1, 2024
2.9 years
September 6, 2024
November 25, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Rate of establishment of exploitable tumor organoid lines
Rate of establishment of tumor organoid lines usable for predictive assays of response to PARP inhibitors.
through study completion, an average of 3 years
Study Arms (1)
tumour and blood collection
tumour and blood collection for realization ex vivo organoid models
Interventions
Eligibility Criteria
Patient with localized endometrial cancer
You may qualify if:
- Patient aged 18 years or more
- Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
- Patient with localized endometrial cancer, presenting:
- A high-grade endometrioid histological type and/or
- P53 mutation and/or
- a non-endometrioid histological type regardless of P53 status.
- Patient affiliated to a social security scheme
- Information and signature of informed consent prior to any specific study procedure
You may not qualify if:
- Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
- Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre François Baclesse
Caen, France
Related Publications (1)
Gall GL, Cherifi F, Divoux J, Florent R, Christy F, Leconte A, San C, Devillers A, Desmartin G, Lecouflet L, Clarisse B, Ballesta S, Thorel L, Dubois B, Harter V, Rousseau N, Gaichies L, Martin-Francoise S, Le Brun JF, Dolivet E, Rouzier R, Jeanne C, Blanc-Fournier C, Figeac M, Leman R, Castera L, Poulain L, Weiswald LB, Joly F. The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors. BMC Cancer. 2025 Feb 11;25(1):244. doi: 10.1186/s12885-025-13590-6.
PMID: 39934735DERIVED
Biospecimen
blood and tissue
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 6, 2024
First Posted
September 19, 2024
Study Start
November 21, 2024
Primary Completion (Estimated)
October 15, 2027
Study Completion (Estimated)
October 15, 2027
Last Updated
November 26, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share